phase 3 will probably be allowed by fda based on this article
ALS clinics start implanting breathing-assist device under new FDA approval...google it
also guessing the lungs are less wasted then other muscles from constant use whereas other muscles are used less so they have less mass overall for the contractile effect of tirasemtiv
lungs and muscles of the diaphragm on the other hand are kept in constant use and are therefore are more response to tirasemtiv
"He also found an enzyme needed to make tangles after plaques are present. When he blocked that enzyme, plaques form but not tangles. The enzyme is another potential drug target, he said."
...whoever develops this target is the next prana
well that is not correct:
SVN-001 is an ion channel blocking antibody which is potentially the first therapeutic antibody against this target class
its not an antibody drug conjugate the antibody binds directly to the channel
The purpose of this example was to determine the effect of NTP peptide #43 on tissue at sites of injection.
Eight normal rats were injected in the skin and subcutaneously, each in four different foci, and in extremity skeletal muscle, each in two different foci, with NTP peptide #43 in saline in quantities of 100 to 400 mL at concentrations of 0.1-1 mg/mL deUvered from plastic syringes through stainless steel 26 gauge needles.
The animals were observed for 24 hours and painlessly sacrificed at 24 hours. The 48 individual foci of infiltration were excised, fixed in 10% formalin, embedded in paraffin, and stained and examined by standard histopathological methods. SimUar groups of control rats were injected with (1) bovine serum albumin 0.1% in saline, (2) normal human serum, (3) physiological saline, (4) noninfectious bacterial proteins, and (5) control peptides and purified and then examined and sacrificed as above, with the excised foci of injection treated as above.
Injection of NTP peptide # 43 produced abundant acute necrosis of tissue at the injection sites. The necrosis was evident in muscle tissue, subcutaneous connective tissue, and dermis at the sites where NTP peptide #43 was injected. At 24 hours, cells appeared pale, shrunken, and necrotic, and there was infiltration with inflammatory cells. The necrosis correlated with the areas of injection and did not appear to spread far beyond the site of injection.
Apart from the mild areas of inflammation, controls showed no evidence of necrosis or cell loss. In contrast to the NTP peptide # 43 injections where entire fields of muscle fiber layers were necrotic, the controls showed minimal or absent muscle changes. Control injections had mild to minimal acute inflammation at the injection sites and focal microhemorrhages from the needles.
patentWO2002097030A2: Peptides derived from neural thread proteins and their medical use
There is a need for an effective agent that will destroy and either: (i) facilitate without surgery the removal of; or (ii) inhibit the further growth of harmful or unwanted cells and tissue, but will have mainly local effects and minimal or no systemic toxicity.
Neural thread proteins and their related molecules are one class of such agents.
NTP has proven to be an effective agent for causing cell death both in vitro in glioma and neuroblastoma cell cultures and in vivo in normal rodent muscle tissue, subcutaneous connective tissue, and dermis, and in a variety of different human and non-human origin tumors, including mammary carcinoma, skin carcinoma and papilloma, colon carcinoma, glioma of brain, and others in rodent models.
The present invention relates to methods of treating unwanted cellular proliferations, such as benign and malignant tumors, glandular (e.g. prostate) hyperplasia, unwanted facial hair, warts, and unwanted fatty tissue. Such a method comprises administering to a mammal in need a therapeutically effective amount of a peptide comprising amino acid sequences corresponding to part of the amino acid sequence of neural thread protein (NTP).